The effect of a diet based on vegetable and dairy protein in patients with liver cirrhosis

The effect of a diet based on vegetable and dairy protein on serum levels of inflammatory biomarkers and oxidative stress in patients with liver cirrhosis: a randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220426054667N3

Enrollment

Registered

2023-07-02

Start date

2023-06-21

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis. Other and unspecified cirrhosis of liver

Interventions

Intervention 1: Intervention group: A diet based on vegetable and dairy protein. Based on the latest guidelines, in this diet, energy will be calculated 1/3 times REE (using the Harris-Benedict equati

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having liver cirrhosis with a doctor's diagnosis for at least 6 months Age range from 30 to 60 years Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Model for End-Stage Liver Disease (MELD) score greater than 18 or Child-Pugh Class C Active gastrointestinal bleeding Serum creatinine above 1.5 mg/dl during the last month Consumption of alcohol and tobacco during the last 6 months Pregnancy and lactation Suffering from diabetes, pulmonary diseases, psychological disorders, hepatocellular carcinoma and other cancers, heart failure, acute viral hepatitis, cholestatic cirrhosis, autoimmune cirrhosis, other autoimmune diseases, hyperuricemia, musculoskeletal diseases Taking corticosteroids and immunosuppressive medications

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Digital scale.;Height. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Stadiometer.;Body Mass Index (BMI). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Body weight (kilogram) divided by the square of height (meter).;Mid Arm Circumference (MAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Tape.;Triceps skin fold (TSF). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Caliper.;Middle Arm Muscle Circumference (MAMC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: MAC – (3.1416 × TSF) formula.;Interleukin 6. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.;High-sensitivity C-reactive protein (hsCRP). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Immunoturbidometry.;Malondialdehyde (MDA). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity (TAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total bilirubin. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Photometric.;Prothrombin time (PT). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Biochemical kit.;Model for End-Stage Liver Disease score. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: The Model for End-Stage Liver Disease score is calculated using serum bilirubin, serum creatinine, and International No	—

Measure

Time frame

Weight. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Digital scale.;Height. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Stadiometer.;Body Mass Index (BMI). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Body weight (kilogram) divided by the square of height (meter).;Mid Arm Circumference (MAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Tape.;Triceps skin fold (TSF). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Caliper.;Middle Arm Muscle Circumference (MAMC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: MAC – (3.1416 × TSF) formula.;Interleukin 6. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: ELISA.;High-sensitivity C-reactive protein (hsCRP). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Immunoturbidometry.;Malondialdehyde (MDA). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity (TAC). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Total bilirubin. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Photometric.;Prothrombin time (PT). Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: Biochemical kit.;Model for End-Stage Liver Disease score. Timepoint: Before intervention and 12 weeks after the intervention. Method of measurement: The Model for End-Stage Liver Disease score is calculated using serum bilirubin, serum creatinine, and International No

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayyeh Asghari

Tehran University of Medical Sciences

asghari.nut@gmail.com0098 21 889900285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026